Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC) Data on the efficacy and safety of adjuvant
FDA Approves Alectinib for ALK-Positive Lung Cancer Alectinib targets cancer cells that have specific changes, called rearrangements, in the ALK gene The drug has been shown to increase how long people with ALK-positive metastatic NSCLC live and has become a mainstay for treatment of people with this form of lung cancer
Disease characteristics and treatment outcomes in patients . . . This exploratory analysis investigated whether the disease-free survival (DFS) benefit seen with adjuvant alectinib versus chemotherapy in patients with resected, ALK -positive non-small cell lung cancer (NSCLC) from the phase III ALINA study (NCT03456076) was maintained across surgical characteristic subgroups and when re-classifying patients according to the 8th edition of the Cancer Staging
ALK and Lung Cancer - American Lung Association ALK stands for anaplastic lymphoma kinase It was originally described in lymphoma, but most ALK-positive cancers are in non-small cell lung cancer
Anaplastic lymphoma kinase (ALK)-positive advanced non-small . . . INTRODUCTION Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that can be aberrantly expressed in several tumor types In non-small cell lung cancer (NSCLC), chromosomal rearrangements involving the ALK gene loci on chromosome 2 are found in approximately 3 to 5 percent of NSCLC tumors [1,2] The most common ALK rearrangement in NSCLC juxtaposes the 5' end of the echinoderm microtubule
Novel Small Molecule Earns FDA Fast Track Designation in ALK+ . . . Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1 2 trial Investigators are currently evaluating the safety, pharmacokinetics, and preliminary activity of TRI-611 among patients with ALK-positive NSCLC as part of a phase 1 2 study (NCT07491497)
Update 2025: Management of Non‑Small-Cell Lung Cancer - PMC Introduction Lung cancer has remained the leading cause of cancer-related mortality worldwide since the 1950s, posing a significant global health challenge [1] NSCLC, which constitutes the majority of lung cancer cases, has historically been associated with poor outcomes due to its often late diagnosis and limited treatment options [2]